Kura Oncology is a biopharmaceutical company focused on the development of innovative medicines for the treatment of cancer
The company is committed to advancing its proprietary drug candidates that target specific genetic and epigenetic drivers of cancer progression, utilizing their expertise in precision medicine to address unmet medical needs. Through rigorous research and clinical trials, Kura aims to bring transformative therapies to patients suffering from various types of cancer, including rare and hard-to-treat forms. Their goal is to improve outcomes and quality of life for patients by providing targeted treatments that leverage the unique characteristics of their tumors.
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally develop into red blood cells, white blood cells, and platelets. In AML, these abnormal cells accumulate in the bone marrow and interfere with the production of normal blood cells. According to Global Market Insights the Acute Myeloid Leukemia Market was valued at USD 2.1 Billion in 2023 and is estimated to grow at a CAGR of 10.7% between 2024 and 2032. High market growth can be attributed to factors such as advancement in research and technology, surging government initiatives and policies, early diagnosis coupled with efforts to implement screening programs. Also, increasing prevalence of acute myeloid leukemia (AML) is a significant factor driving the growth of the market. The report said: “For instance, according to the American Cancer Society, in 2023, there were about 20,380 new cases of acute myeloid leukemia (AML) in the U.S. alone. Hence, as the population ages, the incidence of AML tends to rise, contributing to a larger patient pool seeking diagnosis and treatment, thereby fostering the market growth. Surging government initiatives and polices play a pivotal role in driving the acute myeloid leukemia industry. Also, increased government funding for medical research, including acute myeloid leukemia research, drive advancements in understanding the molecular basis of AML, leading to the development of innovative therapies and treatment modalities.” Active biotech and pharma companies in the markets this week include Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), Syndax Pharmaceuticals (NASDAQSNDX), Kura Oncology, Inc. NASDAQ: KURANASDAQKURA)(NASDAQ: BMEANASDAQBMEA, Johnson & Johnson (NYSE: JNJNYSE).
Shares of United Parcel Service, Inc. (NYSEUPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales
Kura Oncology, Inc. shares are trading higher Tuesday after the company reported preliminary clinical data from the first 20 patients its Komet-007 Phase 1 dose-escalation trial. Kura reported that all newly diagnosed patients treated with ziftomenib and 7+3 achieved a complete remission (CR) with full count recovery, for a CR rate of 100% (5/5), including four patients with NPM1-m acute myeloid leukemia (AML) and one patient with KMT2A-r AML.
